ReviewArchives of toxicology2026
Chalcones as multitarget modulators in non-small cell lung cancer: mechanistic insights and therapeutic perspectives.
Review in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide, and the search for novel therapeutic strategies is ongoing. Chalcones, a class of naturally occurring and synthetically derived open-chain flavonoid precursors, have attracted attention because of their chemical versatility and broad biological activity. This review synthesizes current findings on the molecular mechanisms through which chalcones exert their effects in NSCLC, including modulation of oxidative stress, epithelial-mesenchymal transition, DNA damage responses, and diverse cell death pathways. Chalcones have been shown to interfere with key signaling cascades, such as TGF-β, PI3K/AKT/mTOR, JAK/STAT, and Wnt/β-catenin, with reported effects on tumor proliferation, migration, invasion, and therapy resistance. Their structural flexibility enables chemical optimization aimed at improve potency, selectivity, and pharmacokinetic profiles, supporting further preclinical investigation. Despite promising preclinical results, challenges remain regarding pharmacokinetics, bioavailability, and context-dependent off-target effects. Future research should prioritize integrated mechanistic studies, structure-activity relationship analyses, selective cytotoxicity assessment, and advanced delivery strategies to improve tumor specificity. Chalcones represent chemically versatile multitarget scaffolds for further optimization in NSCLC, particularly in strategies aimed at exploiting epithelial-mesenchymal plasticity, redox adaptation, and regulated cell death.
Indexed as
Identifiers
42446675What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.